[go: up one dir, main page]

LT2809327T - Hidroksialkilo krakmolas, skirtas vėžio gydymui, sumažinant naviko augimo greičius - Google Patents

Hidroksialkilo krakmolas, skirtas vėžio gydymui, sumažinant naviko augimo greičius

Info

Publication number
LT2809327T
LT2809327T LTEP13701646.5T LT13701646T LT2809327T LT 2809327 T LT2809327 T LT 2809327T LT 13701646 T LT13701646 T LT 13701646T LT 2809327 T LT2809327 T LT 2809327T
Authority
LT
Lithuania
Prior art keywords
cancers
reduction
treatment
tumor growth
growth rates
Prior art date
Application number
LTEP13701646.5T
Other languages
English (en)
Inventor
Martin Westphal
Silke Baasner
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of LT2809327T publication Critical patent/LT2809327T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/718Starch or degraded starch, e.g. amylose, amylopectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00Preparation of derivatives of starch
    • C08B31/08Ethers
    • C08B31/12Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP13701646.5T 2012-01-30 2013-01-30 Hidroksialkilo krakmolas, skirtas vėžio gydymui, sumažinant naviko augimo greičius LT2809327T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592017P 2012-01-30 2012-01-30
EP12153068 2012-01-30
PCT/EP2013/051778 WO2013113747A1 (en) 2012-01-30 2013-01-30 Hydroxyalkyl starch for the treatment of cancers by reduction of tumor growth rates

Publications (1)

Publication Number Publication Date
LT2809327T true LT2809327T (lt) 2018-11-26

Family

ID=48870742

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13701646.5T LT2809327T (lt) 2012-01-30 2013-01-30 Hidroksialkilo krakmolas, skirtas vėžio gydymui, sumažinant naviko augimo greičius
LTEP13714546.2T LT2809329T (lt) 2012-01-30 2013-01-30 Hidroksialkilo krakmolas derinyje su citostatikais, skirti vėžio gydymui, simažinant naviko augimo greičius

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP13714546.2T LT2809329T (lt) 2012-01-30 2013-01-30 Hidroksialkilo krakmolas derinyje su citostatikais, skirti vėžio gydymui, simažinant naviko augimo greičius

Country Status (12)

Country Link
US (4) US20130197211A1 (lt)
EP (3) EP2809329B1 (lt)
CN (1) CN104080463B (lt)
AU (3) AU2013214313B2 (lt)
CA (2) CA2861084A1 (lt)
DK (2) DK2809329T3 (lt)
ES (3) ES2693288T3 (lt)
HR (1) HRP20181754T1 (lt)
LT (2) LT2809327T (lt)
PL (3) PL2809328T3 (lt)
SI (2) SI2809329T1 (lt)
WO (3) WO2013113765A1 (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2658400T3 (es) 2013-07-30 2018-03-09 Fresenius Kabi Deutschland Gmbh Almidón hidroxialquilado para el tratamiento de neoplasias hematológicas
EP2832360A1 (en) * 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide for use in preventing metastasis formation and/or relapse
CN105311051A (zh) * 2014-05-26 2016-02-10 陈松源 具有增加抗肿瘤药物疗效的载体溶媒、制备方法及其给药途径
EA034858B1 (ru) * 2015-01-30 2020-03-30 Фрезениус Каби Дойчланд Гмбх Применение модифицированных полимеров глюкозы для снижения метастазирования опухолей

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19975071I2 (de) 1989-06-16 2000-02-03 Fresenius Ag Hydroxyethylstaerke als Plasmaexpander Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
DE4023788A1 (de) * 1990-07-26 1992-01-30 Schumann Klaus Verwendung einer waessrigen loesung einer poly-(o-hydroxyalkyl)-staerke
DE4310974C2 (de) 1993-04-03 1996-08-01 Fresenius Ag Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation
US6680305B1 (en) 1993-06-04 2004-01-20 Biotime, Inc. Physiologically acceptable aqueous solutions and methods for their use
MX9709471A (es) 1995-06-07 1998-02-28 Univ Washington Complejos metalicos multidentados y metodos para preparar y usar los mismos.
US6207654B1 (en) * 1996-05-03 2001-03-27 Bashir Zikria Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2
DE19907257A1 (de) 1999-02-21 2000-09-14 Bernd Horst Meier Mittel zur Steuerung der Diffusion von Injektionslösungen
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
RU2373222C2 (ru) 2004-03-01 2009-11-20 Б. Браун Мельзунген Аг Гидроксиэтилкрахмал
EP2089363A1 (en) * 2006-11-14 2009-08-19 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN101926770B (zh) * 2009-06-25 2013-07-10 浙江海正药业股份有限公司 载药脂质体及其制备方法
CN101926773B (zh) * 2009-06-25 2013-04-03 浙江海正药业股份有限公司 载药类脂微粒及其制备方法
EP2590678A1 (en) * 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
US20140073779A9 (en) 2010-07-09 2014-03-13 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation

Also Published As

Publication number Publication date
CA2861084A1 (en) 2013-08-08
CN104080463A (zh) 2014-10-01
CN104080463B (zh) 2020-07-10
PL2809327T3 (pl) 2019-02-28
EP2809327B1 (en) 2018-08-01
ES2693288T3 (es) 2018-12-10
PL2809328T3 (pl) 2019-01-31
PL2809329T3 (pl) 2019-01-31
AU2013214567A1 (en) 2014-07-17
EP2809328A1 (en) 2014-12-10
CA2861161A1 (en) 2013-08-08
US20160082036A1 (en) 2016-03-24
SI2809329T1 (sl) 2018-12-31
US20130197212A1 (en) 2013-08-01
EP2809328B1 (en) 2018-08-01
EP2809327A1 (en) 2014-12-10
DK2809329T3 (en) 2018-11-26
AU2013214313B2 (en) 2017-04-06
CA2861161C (en) 2020-12-29
US20130197211A1 (en) 2013-08-01
WO2013113765A1 (en) 2013-08-08
DK2809327T3 (en) 2018-11-26
EP2809329A1 (en) 2014-12-10
HK1202807A1 (en) 2015-10-09
WO2013113747A1 (en) 2013-08-08
ES2698948T3 (es) 2019-02-06
HRP20181754T1 (hr) 2018-12-28
AU2013214295C1 (en) 2017-07-27
WO2013113496A1 (en) 2013-08-08
EP2809329B1 (en) 2018-08-01
US20130196949A1 (en) 2013-08-01
SI2809327T1 (sl) 2018-12-31
AU2013214295B2 (en) 2017-04-06
AU2013214567B2 (en) 2017-06-08
ES2698272T3 (es) 2019-02-01
AU2013214295A1 (en) 2014-07-17
AU2013214313A1 (en) 2014-07-17
LT2809329T (lt) 2018-12-10

Similar Documents

Publication Publication Date Title
IL258612B (en) An anti-angiogenic drug for the treatment of ovarian cancer
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
IL235726A0 (en) Pyrimidine compounds for cancer treatment
IL238942B (en) History of pyrimidine-4,2-diamine for cancer treatment
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
PH12014500248A1 (en) Treatment of breast cancer
PL2804599T3 (pl) Terapia skojarzona do leczenia nowotworu złośliwego
IL263781A (en) Combined treatment of ovarian cancer
EP2903644A4 (en) TREATMENT OF CANCER
SI2809327T1 (sl) Hidroksialkil škrob v kombinaciji s citostatiki za zdravljenje rakov z zmanjševanjem stopenj rasti tumorja
PL2817286T3 (pl) Inhibitory kinazy do leczenia raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
HUE041356T2 (hu) Hidroxialkil-keményítõ a tumor növekedési rátájának csökkentésével történõ rákkezelésre
ZA201405068B (en) Piperazinyl derivatives for the treatment of cancer
ZA201307677B (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
IL233495A0 (en) Combination for cancer treatment
PT2925744T (pt) Derivados de pirimidina-2,4-diamina para tratamento de cancro